Anthony DiGiandomenico - 21 Jan 2026 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Reporting relationship: Director
Issuer ticker: NDRA
Reported as of: 21 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 19:44:04 UTC
Prior SEC filing: 15 Oct 2025
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact

Key filing fact

Anthony DiGiandomenico filed Form 4 for ENDRA Life Sciences Inc. (NDRA) on 23 Jan 2026.

Key facts

This page summarizes Anthony DiGiandomenico's Form 4 filing for ENDRA Life Sciences Inc. (NDRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jan 2026, 19:44.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001083544 Primary reporting owner

Relationship: Director
Address: C/O ENDRA LIFE SCIENCES INC., 3600 GREEN COURT, SUITE 350, ANN ARBOR
Signature: /s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact
Signature date: 23 Jan 2026

Shares, units, or other non-derivative securities reported in this filing.

NDRA transaction

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

Footnote F2

Includes unvested RSUs.